Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: With symptomatic remission and functional recovery as the overarching therapeutic objectives of antidepressant therapy, composite endpoint measures that conjointly consider both aspects of treatment are needed. This analysis evaluated the combined effect of vortioxetine on depressive symptoms and functional capacity in adults with MDD. METHODS: NCT01564862, a multinational, double-blind, placebo-controlled, duloxetine-referenced study, conducted between April 2012 and February 2014, in 602 adult outpatients (18-65 years) with moderate-to-severe MDD (Montgomery-Åsberg Depression Rating Scale (MADRS) ≥ 26), a major depressive episode of ≥ 3 months' duration, and self-reported cognitive symptoms were randomized to once-daily vortioxetine (10 or 20mg), duloxetine (60mg), or placebo for 8 weeks. Assessments included the University of California San Diego Performance-based Skills Assessment (UPSA) and the MADRS. Two versions of UPSA were utilized; UPSA ‒Validation of Intermediate Measures and UPSA Brief form. An aligned UPSA-B (communication and finance items) was examined for sensitivity analysis. Efficacy was analyzed versus placebo according to the dual response (change from baseline in UPSA ≥ 7 and ≥ 9 and reduction in MADRS total score from baseline ≥ 50%). RESULTS: Significantly more vortioxetine-treated patients were classified as dual responders for change in MADRS total score and UPSA score of ≥ 7 (clinically important difference [CID]) (27.4% vs 14.5%; P = 0.004), and change above CID (≥ 9) (23.4% vs 13.9%; P = 0.025). Duloxetine did not differ significantly from placebo for these dual response criteria. Sensitivity analysis using the aligned UPSA-B confirmed these results for vortioxetine. LIMITATIONS: An exploratory analysis of a new dual outcome measure in patients with MDD. CONCLUSIONS: Vortioxetine, but not duloxetine, demonstrated a robust combined effect on depressive symptoms and functional capacity in patients with MDD. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01564862; European Clinical Trials Database [EudraCT] Number 2011-005298-22.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Depression, chronic diseases, and decrements in health: results from the World Health Surveys
Moussavi, S., Chatterji, S., Verdes, E., Tandon, A., Patel, V., & Ustun, B. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61415-9 · Cited by 4,070
Ferrari, A. J., Charlson, F. J., Norman, R. E., Patten, S. B., Freedman, G., Murray, C. J. L., Vos, T., & Whiteford, H. A. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001547 · Cited by 3,115
The Functioning and Well-being of Depressed Patients: Results From the Medical Outcomes Study
Wells, K. B. (1989) · JAMA · doi:10.1001/jama.1989.03430070062031 · Cited by 2,130
The Economic Burden of Adults With Major Depressive Disorder in the United States (2005 and 2010)
Greenberg, P. E., Fournier, A.-A., Sisitsky, T., Pike, C. T., & Kessler, R. C. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09298 · Cited by 1,779
Bang-Andersen, B., Ruhland, T., Jørgensen, M., Smith, G., Frederiksen, K., Jensen, K. G., Zhong, H., Nielsen, S. M., Hogg, S., Mørk, A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101459g · Cited by 606
Sanchez, C., Asin, K. E., & Artigas, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.001 · Cited by 547
Job Performance Deficits Due to Depression
Adler, D. A., McLaughlin, T. J., Rogers, W. H., Chang, H., Lapitsky, L., & Lerner, D. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1569 · Cited by 531
Neurocognitive deficits and disability in major depressive disorder
Jaeger, J., Berns, S., Uzelac, S., & Davis-Conway, S. (2006) · Psychiatry Research · doi:10.1016/j.psychres.2005.11.011 · Cited by 484
Katona, C., Hansen, T., & Olsen, C. K. (2012) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283542457 · Cited by 445
McIntyre, R. S., Lophaven, S., & Olsen, C. K. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000546 · Cited by 433
Self-citationMcKnight, P. E., & Kashdan, T. B. (2009) · Clinical Psychology Review · doi:10.1016/j.cpr.2009.01.005 · Cited by 400
Raskin, J., Wiltse, C. G., Siegal, A., Sheikh, J., Xu, J., Dinkel, J. J., Rotz, B. T., & Mohs, R. C. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.6.900 · Cited by 329
Mahableshwarkar, A. R., Zajecka, J., Jacobson, W., Chen, Y., & Keefe, R. S. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.52 · Cited by 307
Judd, L. L., Schettler, P. J., Solomon, D. A., Maser, J. D., Coryell, W., Endicott, J., & Akiskal, H. S. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.06.014 · Cited by 293
Gualtieri, C. T., & Morgan, D. W. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0712 · Cited by 275
Reppermund, S., Ising, M., Lucae, S., & Zihl, J. (2009) · Psychological Medicine · doi:10.1017/s003329170800411x · Cited by 219
Cognitive dysfunction in major depressive disorder: a state-of-the-art clinical review
Bortolato, B., Carvalho, A., & McIntyre, R. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141130203823 · Cited by 181
Self-citationGreen, M. F., Schooler, N. R., Kern, R. S., Frese, F. J., Granberry, W., Harvey, P. D., Karson, C. N., Peters, N., Stewart, M., Seidman, L. J., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10030414 · Cited by 159
McIntyre, R. S., Xiao, H. X., Syeda, K., Vinberg, M., Carvalho, A. F., Mansur, R. B., Maruschak, N., & Cha, D. S. (2015) · CNS Drugs · doi:10.1007/s40263-015-0263-x · Cited by 145
Self-citationMediators of the association between depression and role functioning
Buist‐Bouwman, M. A., Ormel, J., De Graaf, R., De Jonge, P., Van Sonderen, E., Alonso, J., Bruffaerts, R., Vollebergh, W. A. M., & the ESEMeD/MHEDEA 2000 investigators (2008) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01285.x · Cited by 127
Sheehan, D. V., Harnett-Sheehan, K., Spann, M. E., Thompson, H. F., & Prakash, A. (2011) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328341bb5f · Cited by 124
Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder
McIntyre, R. S., Florea, I., Tonnoir, B., Loft, H., Lam, R. W., & Christensen, M. C. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16m10744 · Cited by 100
Self-citationRomera, I., Perez, V., Menchón, J. M., Delgado-Cohen, H., Polavieja, P., & Gilaberte, I. (2010) · European Psychiatry · doi:10.1016/j.eurpsy.2009.02.007 · Cited by 91
Lam, R. W., Parikh, S. V., Michalak, E. E., Dewa, C. S., & Kennedy, S. H. (2015) · Annals of Clinical Psychiatry · doi:10.1177/104012371502700209 · Cited by 62
Cited by
The efficacy of vortioxetine on anhedonia in patients with major depressive disorder
Cao, B., Park, C., Subramaniapillai, M., Lee, Y., Iacobucci, M., Mansur, R. B., Zuckerman, H., Phan, L., & McIntyre, R. S. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00017 · Cited by 139
Self-citationFagiolini, A., Florea, I., Loft, H., & Christensen, M. C. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.11.106 · Cited by 127
Self-citationVortioxetine: a novel antidepressant for the treatment of major depressive disorder
Gonda, X., Sharma, S. R., & Tarazi, F. I. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1546691 · Cited by 123
De Diego-Adeliño, J., Crespo, J. M., Mora, F., Neyra, A., Iborra, P., Gutiérrez-Rojas, L., & Salonia, S. F. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2019705 · Cited by 67
Metadata
- Authors
- Christensen, M. C., Loft, H., & McIntyre, R. S.
- Venue
- Journal of Affective Disorders
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 227
- Pages
- 787-794
- ISSN
- 0165-0327 (ISSN-L)
- OpenAlex
- W2769874827
- Cited by
- 46
- References
- 24
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.